XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.…
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
XBiotech (NASDAQ: XBIT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 87 employees.
The shares were at 1.730 USD on 20 November 2026, down 27.6% over 52 weeks. Its 52-week range is 1.610 USD to 3.440 USD: the price is 49.7% below the high and 7.4% above the low.
Its market capitalisation is 52.74M USD.
XBiotech reports return on equity of -32.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 109.53M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.